SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+14.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$736M
AUM Growth
+$736M
(+18%)
Cap. Flow
+$81.5M
Cap. Flow
% of AUM
11.07%
Top 10 Holdings %
Top 10 Hldgs %
43.9%
Holding
92
New
21
Increased
19
Reduced
26
Closed
16
Top Buys
| 1 |
Illumina
ILMN
|
$28.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$28.5M |
| 3 |
Eli Lilly
LLY
|
$26.1M |
| 4 |
Charles River Laboratories
CRL
|
$25.4M |
| 5 |
Envista
NVST
|
$15.7M |
Top Sells
| 1 |
Viridian Therapeutics
VRDN
|
$16.8M |
| 2 |
AnaptysBio
ANAB
|
$14.8M |
| 3 |
AngioDynamics
ANGO
|
$13M |
| 4 |
United Therapeutics
UTHR
|
$12.7M |
| 5 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$11.7M |
Sector Composition
| 1 | Healthcare | 92.93% |
| 2 | Consumer Staples | 4.27% |
| 3 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $49.2M | 6.68% | 234,859 -60,682 | -21% | -$12.7M |
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $44.9M | 6.1% | 2,502,601 +1,588,255 | +174% | +$28.5M |
|
|
EDAP
3
EDAP TMS
EDAP
$84.5M
| $40.3M | 5.48% | 4,889,745 +1,605,556 | +49% | +$13.2M |
|
4
The Beauty Health Co
SKIN
$264M
| $31.4M | 4.27% | 2,665,876 -610,161 | -19% | -$7.19M |
|
|
5
Illumina
ILMN
$15.8B
| $28.9M | 3.93% | +151,600 | New | +$28.9M |
|
6
CVS Health
CVS
$92.8B
| $27.3M | 3.7% | 285,900 +66,500 | +30% | +$6.34M |
|
7
BioAtla
BCAB
$26.7M
| $26.2M | 3.56% | 3,400,503 +137,800 | +4% | +$1.06M |
|
|
8
Eli Lilly
LLY
$657B
| $26.1M | 3.55% | +80,800 | New | +$26.1M |
|
|
9
Charles River Laboratories
CRL
$8.04B
| $25.4M | 3.45% | +129,100 | New | +$25.4M |
|
10
Surmodics
SRDX
$487M
| $23.4M | 3.17% | 768,478 +107,474 | +16% | +$3.27M |
|
11
Arcellx
ACLX
$3.85B
| $23.3M | 3.16% | 1,239,913 +330,174 | +36% | +$6.2M |
|
12
Organogenesis Holdings
ORGO
$653M
| $21M | 2.86% | 6,489,063 +1,202,896 | +23% | +$3.9M |
|
13
iRadimed
IRMD
$921M
| $20.6M | 2.8% | 684,690 +63,925 | +10% | +$1.92M |
|
14
Tandem Diabetes Care
TNDM
$845M
| $19.9M | 2.7% | 415,200 +231,400 | +126% | +$11.1M |
|
|
THER
15
DELISTED
THERATECHNOLOGIES INC COM
THER
| $19M | 2.58% | 8,007,714 +185,302 | +2% | +$439K |
|
|
16
Envista
NVST
$3.52B
| $15.7M | 2.14% | +480,000 | New | +$15.7M |
|
17
Krystal Biotech
KRYS
$4.27B
| $14.5M | 1.96% | 207,332 -7,150 | -3% | -$498K |
|
18
C4 Therapeutics
CCCC
$185M
| $12.6M | 1.72% | 1,441,513 +1,158,873 | +410% | +$10.2M |
|
19
Amylyx Pharmaceuticals
AMLX
$836M
| $12.1M | 1.64% | +429,336 | New | +$12.1M |
|
20
Natera
NTRA
$23.1B
| $12.1M | 1.64% | 275,673 +143,800 | +109% | +$6.3M |
|
21
Inspire Medical Systems
INSP
$2.77B
| $12M | 1.62% | 67,400 -21,550 | -24% | -$3.82M |
|
|
CUTR
22
DELISTED
Cutera, Inc.
CUTR
| $11.7M | 1.58% | 255,792 -1,808 | -0.7% | -$82.4K |
|
|
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $10.9M | 1.48% | 535,358 -280,382 | -34% | -$5.69M |
|
24
CVRx
CVRX
$205M
| $9.88M | 1.34% | 1,059,040 | – | – |
|
25
Iovance Biotherapeutics
IOVA
$807M
| $9.82M | 1.33% | 1,025,200 +305,600 | +42% | +$2.93M |
|